

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): LaBelle et al.)	Examiner:	Kosson, Rosanne
Serial No.:	10/658,541)	Art Unit:	1651
Filed:	September 8, 2003)		
_				

For:

NANOENGINEERED BIOPHOTONIC HYBRID DEVICE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. These references are also listed on the enclosed PTO Form 1449 and copies are enclosed.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

03/17/2005 EABUBAK1 00000049 10658541

02 FC:1806

180.00 OP

1257433

	This Information Disclosure Statement is being filed:
	within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. §1.97 (b)
\boxtimes	after three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or after the mailing date of a first Office Action on the merits, but <u>before</u> the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):
	the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below)
	OR
	the fee of \$180 set forth in 37 C.F.R. § 1.17(p) (see "Fees" below).
	after a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see "Certification" below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see "Fees" and "Method of Payment of Fees" below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.
CERT	<u>IFICATION</u>
	The undersigned hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
	The undersigned hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

1257433 2

FEES

	No fee is owed by the applicant(s).
\boxtimes	The IDS Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
	The Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i) is enclosed herewith

METHOD OF PAYMENT OF FEES

\boxtimes	Attached is a check in the amount of \$180.00.
\boxtimes	Charge Deposit Account No. 07-0135 in the amount of (any deficiency).

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully Submitted,

GALLAGHER & KENNEDY, P.A.

Date: March 14, 2005

Donna H. Catalfio Reg. No. 55,973

Gallagher & Kennedy, P.A. 2575 East Camelback Road Phoenix, Arizona 85016-9225 Tel No. (602) 530-8028 Fax No. (602) 530-8500 dhc@gknet.com

1257433 3

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der trie Paperwork Red te 6 form 1449/PTO	uction A	ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number Complete if Known	Γ. \
PADI	16107 101111 1449/P1O			Application Number	10/658,541	
ÎNF	ORMATION	DIS	CLOSURE	Filing Date	September 8, 2003	_
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Jeffrey T. LaBelle	Ī
	/line no many cha	ata aa m	anacand.	Art Unit	1651	Ī
(Use as many sheets as necessary)		Examiner Name	Rosanne Kosson			
Sheet	1	of	1	Attorney Docket Number	9138-0092US	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ARELLANO, Juan B. et al, "Effect of Carotenoid Biosynthesis inhibition on the chlorosome organization," Photochemistry and Photobiology, 2000, 71 (6): 715-723.	
	2	GEROLA, Paolo D. et al, "A new bacteriochlorophyll a-protein complex associated with chlorosomes of green sulfur bacteri," Biochimica et Biophysica Acta 848 (1986), 69-76.	
	3	ZHU, Y. et al., "Microscopic and spectroscopic studies of untreated and hexanol-treated chlorosomes from Chloroflexus," Biochimica et Biophysica Acta 1232 (1995) 197-207.	
· <u>-</u>			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.